Research progress on the diagnosis and treatment of "double-hit" lymphoma

Huijuan Lv, Ling Dong, Xiaohui Jia, Lingzhe Kong, Xianhuo Wang, Bin Meng, Kai Fu, Huilai Zhang

Research output: Contribution to journalArticle

Abstract

Double-hit lymphoma (DHL) refers to a group of mature B-cell lymphoma with Myc and Bcl-2 or Bcl-6 genomic rearrangements. DHL mainly occurs in patients with diffused large B-cell lymphoma (DLBCL) and B-cell lymphoma unclassifiable (BCLU). Fluorescence in situ hybridization (FISH) is the gold standard for diagnosis and is used as the basis for changing regimen. Double-expression lymphoma (DEL) is more common than cytogenetically defined double-hit cases. Unlike true DHL, which are mostly of GCB type, ~2/3 DEL cases are non-GCB type. The cut-off value for immunohistochemistry of C-myc and Bcl-2 should be defined to detect the presence of concurrent gene rearrangements by FISH. DHL is characterized by relatively special clinical characteristics and unfavorable prognosis. A number of studies have shown that Bcl-6 DHL are more aggressive than Bcl-2 DHL. Other studies indicated that Bcl-6 DHL is similar to Bcl-2 DHL in terms of poor prognosis. Compared with CHOP-like regiment, R-EPOCH/HyperCVAD regimen has good performance on progression free survival (PFS) and even on overall survival (OS). Despite this development, current chemotherapy regimens often have poor efficacy. Novel and specific molecular targeted agents, rather than chemotherapy drugs, may overcome poor prognosis and provide insights into future treatment strategies. On the basis of the above characteristics, DHL is defined as "high grade B-cell lymphoma with Bcl-2/Myc or Bcl-6/Myc double-hit" in the 2016 WHO classification. In this review, we will issue the definition, pathogenesis, and key points of their argument to examine the diagnosis/treatment of the progress of DHL.

Original languageEnglish (US)
Pages (from-to)593-597
Number of pages5
JournalChinese Journal of Clinical Oncology
Volume43
Issue number14
DOIs
StatePublished - Jan 1 2016

Fingerprint

Lymphoma
Research
B-Cell Lymphoma
Therapeutics
Fluorescence In Situ Hybridization
Drug Therapy
Gene Rearrangement
Non-Hodgkin's Lymphoma
Disease-Free Survival
Immunohistochemistry
Survival

Keywords

  • Diagnosis
  • Double-expression lymphoma
  • Double-hit lymphoma
  • Research progress
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Research progress on the diagnosis and treatment of "double-hit" lymphoma. / Lv, Huijuan; Dong, Ling; Jia, Xiaohui; Kong, Lingzhe; Wang, Xianhuo; Meng, Bin; Fu, Kai; Zhang, Huilai.

In: Chinese Journal of Clinical Oncology, Vol. 43, No. 14, 01.01.2016, p. 593-597.

Research output: Contribution to journalArticle

Lv, Huijuan ; Dong, Ling ; Jia, Xiaohui ; Kong, Lingzhe ; Wang, Xianhuo ; Meng, Bin ; Fu, Kai ; Zhang, Huilai. / Research progress on the diagnosis and treatment of "double-hit" lymphoma. In: Chinese Journal of Clinical Oncology. 2016 ; Vol. 43, No. 14. pp. 593-597.
@article{e807e9cd618a4119a17650bc1481a899,
title = "Research progress on the diagnosis and treatment of {"}double-hit{"} lymphoma",
abstract = "Double-hit lymphoma (DHL) refers to a group of mature B-cell lymphoma with Myc and Bcl-2 or Bcl-6 genomic rearrangements. DHL mainly occurs in patients with diffused large B-cell lymphoma (DLBCL) and B-cell lymphoma unclassifiable (BCLU). Fluorescence in situ hybridization (FISH) is the gold standard for diagnosis and is used as the basis for changing regimen. Double-expression lymphoma (DEL) is more common than cytogenetically defined double-hit cases. Unlike true DHL, which are mostly of GCB type, ~2/3 DEL cases are non-GCB type. The cut-off value for immunohistochemistry of C-myc and Bcl-2 should be defined to detect the presence of concurrent gene rearrangements by FISH. DHL is characterized by relatively special clinical characteristics and unfavorable prognosis. A number of studies have shown that Bcl-6 DHL are more aggressive than Bcl-2 DHL. Other studies indicated that Bcl-6 DHL is similar to Bcl-2 DHL in terms of poor prognosis. Compared with CHOP-like regiment, R-EPOCH/HyperCVAD regimen has good performance on progression free survival (PFS) and even on overall survival (OS). Despite this development, current chemotherapy regimens often have poor efficacy. Novel and specific molecular targeted agents, rather than chemotherapy drugs, may overcome poor prognosis and provide insights into future treatment strategies. On the basis of the above characteristics, DHL is defined as {"}high grade B-cell lymphoma with Bcl-2/Myc or Bcl-6/Myc double-hit{"} in the 2016 WHO classification. In this review, we will issue the definition, pathogenesis, and key points of their argument to examine the diagnosis/treatment of the progress of DHL.",
keywords = "Diagnosis, Double-expression lymphoma, Double-hit lymphoma, Research progress, Treatment",
author = "Huijuan Lv and Ling Dong and Xiaohui Jia and Lingzhe Kong and Xianhuo Wang and Bin Meng and Kai Fu and Huilai Zhang",
year = "2016",
month = "1",
day = "1",
doi = "10.3969/j.issn.1000-8179.2016.14.592",
language = "English (US)",
volume = "43",
pages = "593--597",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "14",

}

TY - JOUR

T1 - Research progress on the diagnosis and treatment of "double-hit" lymphoma

AU - Lv, Huijuan

AU - Dong, Ling

AU - Jia, Xiaohui

AU - Kong, Lingzhe

AU - Wang, Xianhuo

AU - Meng, Bin

AU - Fu, Kai

AU - Zhang, Huilai

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Double-hit lymphoma (DHL) refers to a group of mature B-cell lymphoma with Myc and Bcl-2 or Bcl-6 genomic rearrangements. DHL mainly occurs in patients with diffused large B-cell lymphoma (DLBCL) and B-cell lymphoma unclassifiable (BCLU). Fluorescence in situ hybridization (FISH) is the gold standard for diagnosis and is used as the basis for changing regimen. Double-expression lymphoma (DEL) is more common than cytogenetically defined double-hit cases. Unlike true DHL, which are mostly of GCB type, ~2/3 DEL cases are non-GCB type. The cut-off value for immunohistochemistry of C-myc and Bcl-2 should be defined to detect the presence of concurrent gene rearrangements by FISH. DHL is characterized by relatively special clinical characteristics and unfavorable prognosis. A number of studies have shown that Bcl-6 DHL are more aggressive than Bcl-2 DHL. Other studies indicated that Bcl-6 DHL is similar to Bcl-2 DHL in terms of poor prognosis. Compared with CHOP-like regiment, R-EPOCH/HyperCVAD regimen has good performance on progression free survival (PFS) and even on overall survival (OS). Despite this development, current chemotherapy regimens often have poor efficacy. Novel and specific molecular targeted agents, rather than chemotherapy drugs, may overcome poor prognosis and provide insights into future treatment strategies. On the basis of the above characteristics, DHL is defined as "high grade B-cell lymphoma with Bcl-2/Myc or Bcl-6/Myc double-hit" in the 2016 WHO classification. In this review, we will issue the definition, pathogenesis, and key points of their argument to examine the diagnosis/treatment of the progress of DHL.

AB - Double-hit lymphoma (DHL) refers to a group of mature B-cell lymphoma with Myc and Bcl-2 or Bcl-6 genomic rearrangements. DHL mainly occurs in patients with diffused large B-cell lymphoma (DLBCL) and B-cell lymphoma unclassifiable (BCLU). Fluorescence in situ hybridization (FISH) is the gold standard for diagnosis and is used as the basis for changing regimen. Double-expression lymphoma (DEL) is more common than cytogenetically defined double-hit cases. Unlike true DHL, which are mostly of GCB type, ~2/3 DEL cases are non-GCB type. The cut-off value for immunohistochemistry of C-myc and Bcl-2 should be defined to detect the presence of concurrent gene rearrangements by FISH. DHL is characterized by relatively special clinical characteristics and unfavorable prognosis. A number of studies have shown that Bcl-6 DHL are more aggressive than Bcl-2 DHL. Other studies indicated that Bcl-6 DHL is similar to Bcl-2 DHL in terms of poor prognosis. Compared with CHOP-like regiment, R-EPOCH/HyperCVAD regimen has good performance on progression free survival (PFS) and even on overall survival (OS). Despite this development, current chemotherapy regimens often have poor efficacy. Novel and specific molecular targeted agents, rather than chemotherapy drugs, may overcome poor prognosis and provide insights into future treatment strategies. On the basis of the above characteristics, DHL is defined as "high grade B-cell lymphoma with Bcl-2/Myc or Bcl-6/Myc double-hit" in the 2016 WHO classification. In this review, we will issue the definition, pathogenesis, and key points of their argument to examine the diagnosis/treatment of the progress of DHL.

KW - Diagnosis

KW - Double-expression lymphoma

KW - Double-hit lymphoma

KW - Research progress

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85018935072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018935072&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2016.14.592

DO - 10.3969/j.issn.1000-8179.2016.14.592

M3 - Article

VL - 43

SP - 593

EP - 597

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 14

ER -